// App-Quantinova.ai

BSH2020‐OR‐004 : First analysis of the UKALL14 phase 3 randomised trial to determine if the addition of rituximab to standard induction chemotherapy improves EFS in adults with precursor B‐ALL (CRUK/09/006)

Researchers

Presenter

  • D. I. Marks

Principal Investigators

  • A. A. Kirkwood

  • C. J. Rowntree

  • M. Aguiar

  • K. E. Bailey

  • B. Beaton

  • L. Clifton-Hadley

  • E. Lawrie

  • S. Lee

  • A. K. McMillan

  • T. F. Menne

  • R. J. Mitchell

  • A. V. Moorman

  • P. Patrick

  • P. Smith

  • B. Wrench

  • K. Zuborne Alapi

  • A. K. Fielding

Medical Centers

  • Haematology, University Hospital Bristol NHS Trust, Bristol

  • CR UK and UCL Cancer Trials Centre, London

  • Rheumatology, University Hospital of Wales, Cardiff, UK

  • Cancer Institute, UCL, London

  • Oncology, Nottingham University Hospital, Nottingham, UK

  • Haematology, Newcastle University Teaching Hospital

  • Northern Institute for Cancer Research Newcastle University, Newcastle, United Kingdom

  • Barts Cancer Institute, QMUL, London, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • B-lymphocyte antigen CD20

  • Breakpoint Cluster Region

  • Ph chromosome

  • White Blood Cell

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Daunorubicin

  • Asparaginase

  • Vincristine

  • Rituximab

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01085617

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved